RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA
Delisted
RETA was delisted on the 25th of September, 2023.
218 hedge funds and large institutions have $4.57B invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2019 Q4 according to their latest regulatory filings, with 74 funds opening new positions, 80 increasing their positions, 46 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
74% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 46
33% more funds holding
Funds holding: 164 → 218 (+54)
Holders
218
Holding in Top 10
17
Calls
$157M
Puts
$38.8M
Top Buyers
| 1 | +$384M | |
| 2 | +$73.3M | |
| 3 | +$68.6M | |
| 4 |
BlackRock
New York
|
+$59M |
| 5 |
DFO
Duquesne Family Office
New York
|
+$51.8M |
Top Sellers
| 1 | -$40.3M | |
| 2 | -$36.9M | |
| 3 | -$34.7M | |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$26.9M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$21.9M |